INSTANT-SOYBEAN COMBINATION PRODUCT POWDER

Indications

• Ethanol intoxication
• Detoxification in alcohol dependence
• Antiseptic and disinfectant
• Solvent in pharmaceutical preparations

Dosage

Children: Refer to BNF for Children for appropriate dosing information.

Adults: Refer to BNF for specific dosing information based on clinical indications.

Mechanism of action

Ethanol affects the brain’s neurons by altering their membranes, ion channels, enzymes, and receptors. It binds directly to GABA, glycine, NMDA, acetylcholine, and serotonin receptors, enhancing the inhibitory effects of GABA at GABAa receptors and blocking NMDA receptors for glutamate. This results in reduced excitatory neurotransmission, contributing to its sedative effects. Ethanol also acts as a dehydrating agent, disrupting osmotic balance across cell membranes, which enhances its anti-infective properties.

Pharmacodynamics

Ethanol produces cytotoxic effects through dehydration and precipitation of cellular components, leading to bacteriocidal and antifungal actions. It is metabolized primarily in the liver by alcohol dehydrogenase, with 90 to 98% of ethanol oxidized to acetaldehyde and further to acetic acid. The interaction of ethanol with various neurotransmitter receptors modulates neuronal signaling, which is responsible for its psychoactive effects. Chronic exposure leads to tolerance, characterized by adaptive changes in neurotransmitter systems.

Pharmacokinetics

Ethanol is rapidly absorbed from the gastrointestinal tract, with peak blood concentrations occurring approximately 30 to 90 minutes after consumption. It is distributed throughout body water, with a volume of distribution that varies based on fat and water content in the body. Ethanol is primarily metabolized in the liver, with a small fraction excreted unchanged in urine and breath. The elimination half-life can vary significantly based on individual metabolic rates and liver function.

Contra-indications

• Hypersensitivity to ethanol or any of its components
• Severe liver disease
• Active gastrointestinal bleeding
• Acute pancreatitis

Adverse effects

• Drowsiness
• Dizziness
• Nausea
• Vomiting
• Headache
• Impaired coordination
• Dependence and withdrawal symptoms with chronic use

Interactions

• Increased sedation with other CNS depressants (e.g., benzodiazepines, opioids)
• Inhibition of the metabolism of drugs metabolized by CYP2E1
• Potentially increased risk of gastrointestinal bleeding with nonsteroidal anti-inflammatory drugs (NSAIDs)
• May enhance the hypoglycemic effect of antidiabetic medications

Precautions

• Use with caution in patients with a history of alcohol use disorder
• Monitor for signs of liver function impairment
• Avoid use in pregnant women due to potential fetal harm
• Caution in patients with a history of seizure disorders

Pregnancy

Ethanol should be avoided during pregnancy due to the risk of fetal alcohol spectrum disorders.

Breast-feeding

Ethanol is excreted in breast milk; mothers should avoid alcohol consumption during breastfeeding.

Storage

Store in a cool, dry place away from light and tightly closed in its original container.

Formulations

• Oral solutions
• Topical antiseptic solutions
• Medicated syrups

Indications

• Cardiovascular health
• Menopausal symptom relief
• Bone health
• Cholesterol management
• Potential cancer risk reduction

Dosage

Children: Refer to specific product guidelines or consult a healthcare professional for appropriate dosage.

Adults: Refer to specific product guidelines or consult a healthcare professional for appropriate dosage.

Mechanism of action

Soybeans contain isoflavones, which are phytoestrogens that can mimic the effects of estrogen in the body. They exert their effects primarily through binding to estrogen receptors and modulating gene expression related to estrogen-responsive pathways. This interaction can influence various physiological processes, including bone density, lipid metabolism, and hormonal balance.

Pharmacodynamics

The pharmacodynamics of soybeans are attributed to their content of isoflavones, notably genistein and daidzein. These compounds may exhibit antioxidant properties, modulate lipid profiles by lowering LDL cholesterol, and influence bone metabolism. Additionally, the anti-inflammatory effects of soy isoflavones may contribute to cardiovascular benefits. The bioactive compounds in soybeans can also have protective effects against certain cancers, particularly hormone-sensitive types, by interfering with cancer cell growth and proliferation.

Pharmacokinetics

Isoflavones are absorbed in the gastrointestinal tract, with peak plasma concentrations typically occurring within 1 to 3 hours after ingestion. The bioavailability of isoflavones can be influenced by factors such as food matrix, gut microbiota, and individual metabolism. Soy isoflavones undergo extensive metabolism in the liver, resulting in various metabolites, some of which may exhibit different biological activities. The elimination half-life of isoflavones can vary widely, depending on individual factors and the form in which soy is consumed.

Adverse effects

• Allergic reactions
• Gastrointestinal disturbances
• Nausea
• Diarrhea
• Flatulence

Precautions

• Use with caution in individuals with a known allergy to soy products.
• Monitor for potential interactions with anticoagulants, as soybean contains vitamin K.

Pregnancy

Soybean is generally considered safe during pregnancy when consumed in food amounts. However, high doses or supplements should be avoided due to potential hormonal effects.

Breast-feeding

Soybean is likely safe in food amounts during breastfeeding, but high doses or supplements should be approached with caution.

Storage

Store in a cool, dry place, away from direct sunlight. Keep tightly closed to avoid moisture.

Formulations

• Whole soybeans
• Soy flour
• Soy protein isolate
• Soy milk
• Soy oil
• Soy lecithin

Mechanism of action

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. ... Ethanol is known to affect a large number of membrane proteins that participate in signaling pathways such as neurotransmitter receptors, enzymes, and ion channels, and there is extensive evidence that ethanol interacts with a variety of neurotransmitters. The major actions of ethanol involve enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABAa receptors and blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate, an excitatory amine acid (EAA) receptor. Animal studies indicate that the acute effects of ethanol result from competitive inhibition of glycine binding to NMDA receptor and disruption of glutamatergic neurotransmission by inhibiting the response of the NMDA receptor. Persistent glycine antagonism and attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in tolerance to ethanol by enhancing EAA neurotransmission and NMDA receptor upregulation. The latter appears to involve selective increases in NMDA R2B subunit concentrations and other molecular changes in specific brain loci. The abrupt withdrawal of ethanol thus produces a hyperexcitable state that leads to the ethanol withdrawal syndrome and excitotoxic neuronal death. GABA-mediated inhibition, which normally acts to limit excitation, is eliminated during ethanol withdrawal syndrome and further intensifies this excitation. In addition, NMDA receptors function to inhibit the release of dopamine in the nucleus accumbens and mesolimbic structures, which modulate the reinforcing action of addictive xenobiotics such as ethanol. By inhibiting NMDA receptor activity, ethanol could increase dopamine release from the nucleus accumbens and ventral tegmental area and could thus create dependence. Chronic ethanol administration also results in tolerance, dependence, and an ethanol withdrawal syndrome, mediated, in part, by desensitization and or downregulation of GABAa receptors. The development of alcoholic ketoacidosis (AKA) requires that a combination of physical and physiologic events occur. The normal response to starvation and depletion of hepatic glycogen stores is for amino acids to be converted to pyruvate. Pyruvate can serve as a substrate for gluconeogenesis, be converted to acetyl-CoA, which can enter the Krebs cycle or can be utilized in various biosynthetic pathways (eg, fatty acid, ketone bodies, cholesterol, and acetylcholine) ... Ethanol metabolism generates NADH, resulting in an excess of reducing potential. This high redox state favors the conversion of pyruvate to lactate, diverting pyruvate from being a substrate for gluconeogenesis. To compensate for the lack of normal metabolic substrates, the body mobilizes fat from adipose tissue and increased fatty acid metabolism as an alternative source of energy. This response is mediated by a decrease in insulin and an increased secretion of glucagon, catecholamines, growth hormone, and cortisol. Fatty acid metabolism results in the formation of acetyl-CoA and it combines with the excess acetate that is generated from ethanol metabolism to form acetoacetate. Most of the acetoacetate is reduced to beta-hydroxybutyrate due to the excess reducing potential or high redox state of the cell. Volume depletion interferes with the renal elimination of acetoacetate and beta-hydroxybutyrate, and contributes to the acidosis. An elevated lactate concentration may result from shunting from pyruvate or

Pharmacodynamics

Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations. Ethanol also binds to GABA, glycine, NMDA receptors and modulates their effects. Ethanol is also metabolised by the hepatic enzyme alcohol dehydrogenase.